[1] Li X, Zhang J, Huang J, et a1. A multicenter, randomized, double-blind, Parallel-group, Placebo-controlled study of the effects of qiliqiangxin capsules in Patients with chronic heart failure[J]. J A m Coll Cardiol, 2013, 62(12):1065-1072 . [2] 李琳,李琦,王金会,赵培勇.23 例芪苈强心胶囊相关洋地黄过量病例分析[J],中国药物警戒,2015,12(6),357-362. [3] Spencer A Morris, H Floyd Hatcher, Deepa K Reddy. Digoxin therapy for heart failure: an update[J]. Am Fam Physician, 2006, 74(4):613-618 . [4] Miura T,Kojima R,Sugiura Y,et al.Effect of aging on the incidence of Digoxin toxicity[J].The Annals of Pharmacotherapy,2000,34,427-432. [5] Pengqiang Du, AifengWang, et a1. Impactof SLCO4C1 Genotypes, Creatinine,and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency[J]. Clinical Therapeutics, 2020, 42(9):1799-1810 . [6] 叶小春,黄鹤归,张耕.芪苈强心胶囊对地高辛血药浓度的影响[J].医药导报,2019,38(7) :955-957. [7] 任晓亮,谢跃生,潘桂湘,等.香加皮强心成分杠柳毒苷肠菌代谢研究[J].天津中医药,2007,24(6) :515-518. [8] Chen R,Zou SL,Wang ML,et al.Population Pharmacokinetics of Digoxin in elderly patients[J].Eur J Drug Metab Pharmacokinet,2013,38(2),115-121. [9] Krum H,Bigger JT,Goldsimth RL, et al.Effect of Long-Term Digoxin Therapy on Autonomic Function in Patients With Chronic Heart Failure[J]. Journal of the American College of Cardiology, 1995, 25(2) :289-294. |